Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Arena Pharmaceuticals	ChemoCentryx	Eidos Therapeutics	Reata Pharmaceuticals	Hutchison China MediTech
Symbol	NASDAQ:ARNA	NASDAQ:CCXI	NASDAQ:EIDX	NASDAQ:RETA	NASDAQ:HCM
Price Information
Current Price	$65.90	$46.54	$122.21	$90.87	$29.25
52 Week Range	Buy	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	1.7	1.6	1.0	1.4	1.4
Analysis Score	4.5	3.5	1.0	3.5	3.5
Community Score	2.4	2.7	2.3	2.6	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	0.8	0.0
Earnings & Valuation Score	0.0	0.0	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$92.80	$80.78	$54.07	$237.43	$40.00
% Upside from Price Target	40.82% upside	73.57% upside	-55.76% downside	161.28% upside	36.75% upside
Trade Information
Market Cap	$3.98 billion	$3.25 billion	$4.75 billion	$3.29 billion	$4.26 billion
Beta	0.83	1.7	-0.16	1.57	1.12
Average Volume	498,669	485,607	128,113	290,036	236,489
Sales & Book Value
Annual Revenue	$806.43 million	$36.13 million	$26.69 million	$26.52 million	$204.89 million
Price / Sales	4.93	89.84	177.99	124.04	20.79
Cashflow	$6.46 per share	N/A	N/A	N/A	N/A
Price / Cash	10.20	N/A	N/A	N/A	N/A
Book Value	$21.38 per share	$1.14 per share	$4.57 per share	$7.74 per share	$2.35 per share
Price / Book	3.08	40.82	26.74	11.74	12.45
Profitability
Net Income	$397.55 million	$-55,490,000.00	$-37,830,000.00	$-290,170,000.00	$-106,020,000.00
EPS	$7.69	($0.98)	($1.03)	($9.54)	($0.80)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-58.10%	N/A	-4,340.72%	N/A
Return on Equity (ROE)	-33.17%	-17.23%	-65.21%	-163.42%	N/A
Return on Assets (ROA)	-30.41%	-11.07%	-53.04%	-56.49%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.04%	0.05%	0.14%	N/A	0.07%
Current Ratio	23.17%	10.12%	11.10%	12.98%	3.14%
Quick Ratio	23.17%	10.12%	11.10%	12.98%	3.01%
Ownership Information
Institutional Ownership Percentage	89.67%	80.67%	31.40%	64.30%	33.45%
Insider Ownership Percentage	3.05%	9.30%	70.10%	31.70%	N/A
Miscellaneous
Employees	363	133	70	261	1,280
Shares Outstanding	60.34 million	69.74 million	38.87 million	36.20 million	145.62 million
Next Earnings Date	5/6/2021 (Estimated)	5/10/2021 (Estimated)	N/A	5/10/2021 (Estimated)	N/A
Optionable	Optionable	Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Hutchison China MediTech secured $100M equity investment by Baring Private Equity Asia seekingalpha.com - April 9 at 7:54 PM
	HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia finance.yahoo.com - April 8 at 8:26 AM
	Supernus Pharmaceuticals (NASDAQ:SUPN) versus Hutchison China MediTech (NASDAQ:HCM) Financial Analysis americanbankingnews.com - April 5 at 2:14 AM
	Head-To-Head Survey: Hutchison China MediTech (NASDAQ:HCM) vs. Supernus Pharmaceuticals (NASDAQ:SUPN) americanbankingnews.com - April 5 at 2:14 AM
	HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies finance.yahoo.com - March 29 at 3:28 AM
	Financial Analysis: Hutchison China MediTech (NASDAQ:HCM) and Eyenovia (NASDAQ:EYEN) americanbankingnews.com - March 28 at 4:44 PM
	HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million finance.yahoo.com - March 24 at 10:33 AM
	Hutchison China Medi - Vesting of awards under Long Term Incentive Plan proactiveinvestors.co.uk - March 10 at 6:35 AM
	Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates ... apnews.com - March 4 at 7:38 AM
	Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity markets.businessinsider.com - March 4 at 7:38 AM
	Hutchison China MediTech Ltd. to Host Earnings Call finance.yahoo.com - March 4 at 7:38 AM
	Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity finance.yahoo.com - March 4 at 7:38 AM
	Hutchison China Medi - Notice of Results proactiveinvestors.co.uk - February 4 at 8:30 AM
	Hutchison China Meditech (HCM) ORD USD0.10 hl.co.uk - January 23 at 6:48 PM
	Hutchison China Medi - Savolitinib Data to be Presented at Virtual WCLC proactiveinvestors.co.uk - January 15 at 10:15 PM
	Hutchison China Medi - Chi-Med & Inmagene Announce Strategic Partnership proactiveinvestors.co.uk - January 12 at 1:41 AM
	Chi-Med, Inmagene To Develop & Commercialize Portfolio Of Drug Candidates For Immunological Diseases markets.businessinsider.com - January 10 at 9:54 PM
	Hutchison China Medi - Total Voting Rights proactiveinvestors.co.uk - January 1 at 11:16 PM
	Hutchison China Medi - NMPA approval of Surufatinib in China for ep-NET proactiveinvestors.co.uk - December 30 at 1:35 PM
	Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors finance.yahoo.com - December 30 at 8:35 AM
	Hutchison China Medi - US NDA Rolling Submission of Surufatinib Initiated proactiveinvestors.co.uk - December 29 at 9:07 AM
	Hutchison China Files US FDA Drug Application For Cancer Treatment lse.co.uk - December 29 at 9:07 AM
	Hutchison China Medi - Chi-Med to Present at JPM proactiveinvestors.co.uk - December 22 at 2:13 PM
	Should I Avoid Hutchison China MediTech Limited (HCM)? finance.yahoo.com - December 1 at 2:27 AM
	China NMPA accepts for review Chi-Med’s NDA for surufatinib to treat advanced pancreatic neuroendocrine tumors pharmabiz.com - September 19 at 10:03 AM

Date	Company	Brokerage	Action
4/15/2021	Arena Pharmaceuticals	Needham & Company LLC	Reiterated Rating
4/13/2021	Arena Pharmaceuticals	Credit Suisse Group	Boost Price Target
4/1/2021	Arena Pharmaceuticals	HC Wainwright	Boost Price Target
3/9/2021	Arena Pharmaceuticals	Cantor Fitzgerald	Lower Price Target
3/3/2021	Arena Pharmaceuticals	SVB Leerink	Lower Price Target
3/3/2021	Arena Pharmaceuticals	Jonestrading	Lower Price Target
11/19/2020	Arena Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
11/19/2020	Arena Pharmaceuticals	Smith Barney Citigroup	Initiated Coverage
11/10/2020	Arena Pharmaceuticals	Guggenheim	Lower Price Target
11/10/2020	Arena Pharmaceuticals	Royal Bank of Canada	Lower Price Target
11/2/2020	Arena Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
9/30/2020	Arena Pharmaceuticals	Bank of America	Boost Price Target
8/6/2020	Arena Pharmaceuticals	Wells Fargo & Company	Boost Price Target
3/8/2021	ChemoCentryx	Raymond James	Boost Price Target
3/8/2021	ChemoCentryx	Stifel Nicolaus	Initiated Coverage
10/29/2020	ChemoCentryx	Piper Sandler	Boost Price Target
6/16/2020	ChemoCentryx	BTIG Research	Initiated Coverage
6/3/2020	ChemoCentryx	Canaccord Genuity	Reiterated Rating
10/6/2020	Eidos Therapeutics	BMO Capital Markets	Downgrade
5/11/2020	Eidos Therapeutics	Barclays	Lower Price Target
11/19/2019	Eidos Therapeutics	Piper Jaffray Companies	Boost Price Target
11/1/2019	Eidos Therapeutics	Roth Capital	Boost Price Target
6/12/2020	Reata Pharmaceuticals	Robert W. Baird	Reiterated Rating
4/17/2020	Reata Pharmaceuticals	Jefferies Financial Group	Boost Price Target
11/13/2019	Reata Pharmaceuticals	National Securities	Downgrade
2/16/2021	Hutchison China MediTech	Mizuho	Initiated Coverage
10/2/2020	Hutchison China MediTech	Deutsche Bank Aktiengesellschaft	Initiated Coverage
2/20/2020	Hutchison China MediTech	The Goldman Sachs Group	Initiated Coverage
11/19/2019	Hutchison China MediTech	CLSA	Initiated Coverage
7/5/2019	Hutchison China MediTech	Macquarie	Initiated Coverage
3/27/2019	Hutchison China MediTech	HSBC	Initiated Coverage

(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources